Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease

被引:18
|
作者
Mendoza, Yuly [1 ]
Cocciolillo, Sila [2 ]
Chen, Tianyan [1 ]
Margini, Cristina [2 ]
Sebastiani, Giada [1 ]
Berzigotti, Annalisa [2 ]
Murgia, Giuseppe [1 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Univ Clin Visceral Surg & Med,Dept Biomed Res, Bern, Switzerland
[2] McGill Univ, Royal Victoria Hosp, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
Cirrhosis; Ultrasound; NASH; Fibrosis; CONTROLLED ATTENUATION PARAMETER; STIFFNESS MEASUREMENT; RISK; COMPLICATIONS; PREDICTION; FIBROSIS;
D O I
10.1016/j.cgh.2020.04.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Some patients with compensated advanced chronic liver disease (cACLD) require use of an extralarge probe for liver stiffness measurement (LSM), owing to overweight or obesity. However, the ability of noninvasive markers of portal hypertension and the controlled attenuation parameter (CAP) to determine which of these patients are at risk for decompensation has not been fully assessed. METHODS: We collected data from 272 patients with cACLD (LSM double dagger 10 kPa by XL probe; 57% with nonalcoholic steatohepatitis; mean body mass index, 33.8 6.5 kg/m2; median Child-Pugh score, 5; median LSM, 16.8 kPa; mean CAP, 318 66 dB/m) evaluated at 2 academic centers from 2015 through 2018. We collected clinical data on decompensation (ascites, portal hypertension bleeding, jaundice, hepatic encephalopathy) and severe bacterial infections; patients were followed up for a median of 17 months (interquartile range, 11-24 mo). We evaluated associations between these events and LSM, CAP, LSM*spleen size/platelet count (LSPS), and portal hypertension risk scores. RESULTS: Decompensation occurred in 12 patients and severe bacterial infections developed in 5 patients. LSM, LSPS, and the portal hypertension risk score identified patients with decompensation with area under the receiver operating characteristic curve values of 0.848 (95% CI, 0.720-0.976; P < .0001), 0.881 (95% CI, 0.798-0.954; P < .0001), and 0.890 (95% CI, 0.814-0.966; P < .0001), respectively. In multivariate Cox regression analysis, in patients with nonalcoholic steatohepatitis, LSM and CAP were associated independently with decompensation and severe bacterial infection; CAP >= 220 dB/m was associated with a reduced risk of decompensation (hazard ratio, 0.043, 95% CI, 0.004-0.476; P =.01). CONCLUSIONS: LSM, LSPS, and the portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection.
引用
收藏
页码:3017 / +
页数:15
相关论文
共 50 条
  • [1] Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
    Pons, Monica
    Augustin, Salvador
    Scheiner, Bernhard
    Guillaume, Maeva
    Rosselli, Matteo
    Rodrigues, Susana G.
    Stefanescu, Horia
    Ma, Mang M.
    Mandorfer, Mattias
    Mergeay-Fabre, Mayka
    Procopet, Bogdan
    Schwabl, Philipp
    Ferlitsch, Arnulf
    Semmler, Georg
    Berzigotti, Annalisa
    Tsochatzis, Emmanuel
    Bureau, Christophe
    Reiberger, Thomas
    Bosch, Jaime
    Abraldes, Juan G.
    Genesca, Joan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (04) : 723 - 732
  • [2] Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
    Vuille-Lessard, Elise
    Rodrigues, Susana G.
    Berzigotti, Annalisa
    CLINICS IN LIVER DISEASE, 2021, 25 (02) : 253 - 289
  • [3] Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease
    Jindal, Ankur
    Agarwal, Samagra
    Sharma, Sanchit
    Kumar, Manoj
    Saraya, Anoop
    Sarin, Shiv Kumar
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (05) : 2149 - 2157
  • [4] Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension
    Pastrovic, Frane
    Novak, Rudjer
    Grgurevic, Ivica
    Hrkac, Stela
    Salai, Grgur
    Zarak, Marko
    Grgurevic, Lovorka
    PLOS ONE, 2024, 19 (04):
  • [5] Secondary hyperaldosteronism and liver fibrosis in patients with compensated chronic liver disease or portal hypertension
    Vitale, Giovanni
    Coscia, Kimberly
    Zavatta, Guido
    Morelli, Maria Cristina
    Vicennati, Valentina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 99 : 118 - 120
  • [6] Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension
    Semmler, Georg
    Hartl, Lukas
    Mendoza, Yuly Paulin
    Simbrunner, Benedikt
    Jachs, Mathias
    Balcar, Lorenz
    Schwarz, Michael
    Hofer, Benedikt Silvester
    Fritz, Laurenz
    Schedlbauer, Anna
    Stopfer, Katharina
    Neumayer, Daniela
    Maurer, Jurij
    Szymanski, Robin
    Meyer, Elias Laurin
    Scheiner, Bernhard
    Quehenberger, Peter
    Trauner, Michael
    Aigner, Elmar
    Berzigotti, Annalisa
    Reiberger, Thomas
    Mandorfer, Mattias
    HEPATOLOGY, 2024, 80 (04) : 791 - 806
  • [7] Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
    Raeven, Pierre
    Baron-Stefaniak, Joanna
    Simbrunner, Benedikt
    Stadlmann, Alexander
    Schwabl, Philipp
    Scheiner, Bernhard
    Schaden, Eva
    Eigenbauer, Ernst
    Quehenberger, Peter
    Mandorfer, Mattias
    Baron, David Marek
    Reiberger, Thomas
    HEPATOLOGY INTERNATIONAL, 2020, 14 (06) : 1083 - 1092
  • [8] A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
    Dajti, Elton
    Ravaioli, Federico
    Marasco, Giovanni
    Alemanni, Luigina Vanessa
    Colecchia, Luigi
    Ferrarese, Alberto
    Cusumano, Caterina
    Gemini, Stefano
    Vestito, Amanda
    Renzulli, Matteo
    Golfieri, Rita
    Festi, Davide
    Colecchia, Antonio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (11) : 1825 - 1833
  • [9] Use of Noninvasive Markers of Portal Hypertension and Timing of Screening Endoscopy for Gastroesophageal Varices in Patients With Chronic Liver Disease
    Berzigotti, Annalisa
    Bosch, Jaime
    Boyer, Thomas D.
    HEPATOLOGY, 2014, 59 (02) : 729 - 731
  • [10] Prevention of First Decompensation in Advanced Chronic Liver Disease
    Mandorfer, Mattias
    Simbrunner, Benedikt
    CLINICS IN LIVER DISEASE, 2021, 25 (02) : 291 - 310